Biosimilar changes ASP outpacing reimbursement making not affordable to use Working with CMS but needs further legislation to fix this FDA may change interchangeability status for medications to no longer require switching studies @ACRheumDC @RheumNow #ACR24 https://t.co/daYQJvsHRG